Epsilon Healthcare Ltd (ASX: EPN) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Epsilon Healthcare Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$8.56 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
389.10 million
Earnings per share
-0.003
Dividend per share
N/A
Year To Date Return
-33.33%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Epsilon Healthcare Ltd (ASX: EPN)
Latest News
⏸️ Investing
Why I think Auscann Group Holdings Ltd is the best pot stock to buy
⏸️ Investing
These pot stocks have been on fire in 2018
⏸️ Investing
ALL ORDINARIES finishes higher Friday: 9 shares you missed
⏸️ Investing
Why BOD Australia Ltd jumped 40% in a day
⏸️ Investing
ALL ORDINARIES finishes higher Thursday: 10 shares you missed
⏸️ Investing
Pot stocks rocket on regulation change
⏸️ Investing
Why Aussie pot stocks are smoking the market today
⏸️ Investing
ALL ORDINARIES finishes higher Thursday: 7 shares you missed
⏸️ Investing
Pot stocks are flying high today
⏸️ Investing
Why these 4 ASX shares fell into the red today
⏸️ Investing
Here are 2017's best performing ASX pot stocks
⏸️ Investing
Why Hydroponics Company Ltd shares smoked the market on Thursday
EPN ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Epsilon Healthcare Ltd
Epsilon Healthcare Ltd is an Australian based, globally active healthcare organisation. It operates a diversified and vertically integrated portfolio of assets, including healthcare and clinics operation, pharmaceutical contract development and manufacturing operation & pharmacy services. The company offers end-to-end solutions across the healthcare spectrum: from product development and manufacturing to patient care. The company's three (3) main operating segments are: a. Contract Development and Manufacturing activities, b. Telehealth medical practice services; and c. Pharmacy services. The majority of revenue is derived from the Contract Development and Manufacturing activities segment.
EPN Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 14 Jul 2026 | $0.02 | $0.00 | 0.00% | 800 | $0.02 | $0.02 | $0.02 |
| 13 Jul 2026 | $0.02 | $0.00 | 0.00% | 67,333 | $0.02 | $0.02 | $0.02 |
| 10 Jul 2026 | $0.02 | $0.00 | 0.00% | 3,553 | $0.02 | $0.02 | $0.02 |
| 08 Jul 2026 | $0.02 | $0.00 | 0.00% | 47,043 | $0.02 | $0.02 | $0.02 |
| 07 Jul 2026 | $0.02 | $0.00 | 0.00% | 190,000 | $0.02 | $0.02 | $0.02 |
| 06 Jul 2026 | $0.02 | $0.00 | 0.00% | 1,342 | $0.02 | $0.02 | $0.02 |
| 03 Jul 2026 | $0.02 | $0.00 | 0.00% | 143,480 | $0.02 | $0.02 | $0.02 |
| 02 Jul 2026 | $0.02 | $0.00 | 0.00% | 171 | $0.02 | $0.02 | $0.02 |
| 30 Jun 2026 | $0.02 | $0.00 | 0.00% | 262,222 | $0.02 | $0.02 | $0.02 |
| 29 Jun 2026 | $0.02 | $0.00 | 0.00% | 49,186 | $0.02 | $0.02 | $0.02 |
| 26 Jun 2026 | $0.02 | $0.00 | 0.00% | 104,914 | $0.02 | $0.02 | $0.02 |
| 25 Jun 2026 | $0.02 | $0.00 | 0.00% | 64,409 | $0.02 | $0.02 | $0.02 |
| 24 Jun 2026 | $0.02 | $0.00 | 0.00% | 51,378 | $0.02 | $0.02 | $0.02 |
| 23 Jun 2026 | $0.02 | $0.00 | 0.00% | 243,038 | $0.02 | $0.02 | $0.02 |
| 22 Jun 2026 | $0.02 | $0.00 | 0.00% | 106,548 | $0.02 | $0.02 | $0.02 |
| 19 Jun 2026 | $0.02 | $0.00 | 0.00% | 137,355 | $0.02 | $0.02 | $0.02 |
| 18 Jun 2026 | $0.02 | $0.00 | 0.00% | 47,327 | $0.02 | $0.02 | $0.02 |
| 17 Jun 2026 | $0.02 | $0.00 | 0.00% | 111,579 | $0.02 | $0.02 | $0.02 |
| 16 Jun 2026 | $0.02 | $0.00 | 0.00% | 70,334 | $0.02 | $0.02 | $0.02 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 03 Jul 2026 | Zoe Hutchings | Buy | 1,500,000 | $30,000 |
Off-market trade.
|
| 05 Jun 2026 | Peter Giannopoulos | Issued | 22,000,000 | $506,000 |
Issue of options.
|
| 05 Jun 2026 | Alan Beasley | Issued | 10,000,000 | $230,000 |
Issue of options.
|
| 11 May 2026 | Alan Beasley | Buy | 100,000 | $2,010 |
On-market trade. Brokerage included
|
| 07 May 2026 | Alan Beasley | Buy | 298,854 | $6,300 |
On-market trade. Brokerage included
|
| 06 May 2026 | Alan Beasley | Buy | 15,759 | $320 |
On-market trade. Brokerage included
|
| 05 May 2026 | Alan Beasley | Buy | 185,387 | $3,722 |
On-market trade. Brokerage included
|
| 08 Jan 2026 | Zoe Hutchings | Buy | 307,934 | $10,856 |
On-market trade. 10,856.78 (including brokerage)
|
| 30 Dec 2025 | Zoe Hutchings | Buy | 519,426 | $19,106 |
On-market trade. including brokerage
|
| 19 Dec 2025 | Zoe Hutchings | Buy | 40,000 | $1,004 |
On-market trade.
|
| 25 Jul 2025 | Peter Giannopoulos | Issued | 25,000,000 | $600,000 |
Issue of options.
|
| 25 Jul 2025 | Alan Beasley | Issued | 10,000,000 | $240,000 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Alan Preston Beasley | Non-Executive DirectorNon-Executive Chairman | Aug 2016 |
Mr Beasley is a company director with over 30 years of experience, having served many small, medium and large company Boards including startups, IPOs and turnarounds. A former director of the Australian subsidiaries of Bankers Trust, Goldman Sachs and BNP Paribas, Alan has the corporate reach, expertise and experience to advise and assist the company in the corporate and capital markets environment.
|
| Mr Peter Giannopoulos | Chief Executive OfficerExecutive Director | May 2023 |
Mr Giannopoulos brings more than 25 years of experience across the Australian healthcare ecosystems. Previously Peter was CEO of Cell Therapies Pty Ltd, an Australian based globally active commercial contract development and manufacturing company with a specialization in cell and gene therapies and cellular immunotherapy products.
|
| Ms Zoe Hutchings | Non-Executive Director | Jun 2024 |
Ms Hutchings has a career leading pharmaceutical and healthcare business units to identify opportunities for diversification, growth and to realize long term profitability in multiple geographical jurisdictions. Her leadership of the company-wide strategy at Sandoz Pharmaceuticals, encompassing a start-up business unit and cross company strategy, led to a return to margin accretive growth. Concurrently, Zoe has skills acquired in the pharmaceutical and healthcare industry in multi-product franchises, at various product life cycle stages from launch to patent expiry, to generic portfolios.
|
| Mr Daniel Kaplon | Chief Financial OfficerCompany Secretary | Aug 2025 |
-
|
| Daniel Kaplon | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Watercrest Asset Management Pty Ltd | 35,828,878 | 9.21% |
| Alexander Hotel Investments Pty Ltd | 21,250,000 | 5.46% |
| Cyrene Holdings Pty Ltd <Cyrene A/C> | 16,771,121 | 4.31% |
| Mr Lloyd Stafford Taylor | 12,687,088 | 3.26% |
| Mr Craig Graeme Chapman <Nampac Discretionary A/C> | 10,911,556 | 2.80% |
| HSBC Custody Nominees (Australia) Limited | 10,517,481 | 2.70% |
| Mr Alan Preston Beasley | 10,500,000 | 2.70% |
| Dash & Co Assets Pty Ltd <Dash And Co Super Fund A/C> | 10,000,000 | 2.57% |
| Fennell Church Pty Limited <Fennell Church Prop Unit A/C> | 8,438,499 | 2.17% |
| Health360 Investment Management Inc | 7,052,880 | 1.81% |
| Giannopoulos Superannuation Nominees Pty Ltd <Giannopoulos Super Fund A/C> | 7,000,000 | 1.80% |
| S Bentley & Co Pty Ltd <S Bentley & Co Family A/C> | 5,555,556 | 1.43% |
| Hollow Sword Blade Company Pty Ltd | 4,000,000 | 1.03% |
| Mr Gary John Radcliff & Mrs Debbi Lee Radcliff | 3,955,700 | 1.02% |
| Barcoo Holdings Pty Ltd <Wyan Family Investments> | 3,795,824 | 0.98% |
| BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 3,540,844 | 0.91% |
| Mr George Daaboul | 3,000,000 | 0.77% |
| Meta Growth Corp | 2,942,489 | 0.76% |
| Ms Cherese Richelle Taylor & Mr Lauie Gabriel Dok | 2,940,000 | 0.76% |
| Celtic Capital Pty Ltd | 2,888,872 | 0.73% |